Following announcement of June 30, 2006 of its exercise of option to acquire the remaining 60% of Sun Biomedical Laboratories, Inc. for $1,680,000, Harrington Group continues to position itself for its global expansion of sales for its illicit drug testing products through its 100% subsidiary.

This press release is available on the Company's official on-line Investor Relations HUB at http://www.agoracom.com/IR/MDMGroup for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to MDDM@agoracom.com where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time. Also see www.mdmgroupinc.com.

About MDM Group, Inc.

MDM Group develops strategic interests within the Security, Biodefense, Law Enforcement and Homeland Security industries. MDM Group's Biodefense Division is focused on discovery and rapid development of vaccines and other countermeasures to support the Homeland Defense and other stockpile requirements of the United States government and its citizens as well as those in other countries. MDM Group has a controlling interest in Australian listed Harrington Group which is also quoted in the US on the OTC: HGRLF.PK.

Safe Harbor Statement

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.